In late June and early July 2026, Revolution Medicines reported Phase 1/2 data showing that its RAS G12D inhibitor zoldonrasib, alone and in combination with chemotherapy or daraxonrasib, produced high response and disease control rates with manageable safety in metastatic pancreatic ductal adenocarcinoma, supporting ongoing and planned Phase 3 RASolute trials.
An important implication is that Revolution Medicines now has early clinical evidence for a targeted approach in RAS G12D pancreatic cancer, a setting with no approved targeted therapies and high unmet medical need, potentially broadening how investors view the depth and coherence of its RAS(ON) pipeline.
We’ll now look at how these early zoldonrasib combination results in RAS G12D pancreatic cancer influence Revolution Medicines’ investment narrative.
We’ve uncovered the 7 dividend fortresses yielding 5%+ that don’t just survive market storms, but thrive in them.
Revolution Medicines Investment Narrative Recap
To own Revolution Medicines today, you need to believe its RAS(ON) platform can convert multiple late stage trials into meaningful, durable oncology franchises despite heavy cash burn and ongoing losses. The new zoldonrasib pancreatic data reinforces the importance of RASolute 305 and 309 as near term clinical catalysts, while also underscoring the key risk that concentrated dependence on RAS programs leaves little room for disappointment if pivotal results or regulatory outcomes fall short.
Among recent announcements, the completion of a US$1.5 billion follow on equity raise in April stands out here. It extends the company’s cash runway to support expensive Phase 3 programs like RASolute 305 and the planned RASolute 309 trial, but also highlights how Revolution Medicines is leaning on external capital while it builds a commercial footprint ahead of any product revenue, amplifying execution and financing risks if timelines or trial outcomes shift.
Yet behind the excitement around early zoldonrasib data, investors should still be mindful that…
Read the full narrative on Revolution Medicines (it’s free!)
Revolution Medicines’ narrative projects $1.0 billion revenue and $148.6 million earnings by 2029. This implies an earnings increase of about $1.3 billion from -$1.1 billion today.
Uncover how Revolution Medicines’ forecasts yield a $133.70 fair value, a 29% downside to its current price.
Exploring Other Perspectives 
RVMD 1-Year Stock Price Chart
The most cautious analysts, who saw only about US$838.8 million of revenue and US$158.7 million of earnings by 2029, paint a far tougher path than consensus, reminding you that credible views on Revolution Medicines can diverge sharply and that both bullish and bearish narratives may need to be revisited as the new zoldonrasib results feed into expectations.
Explore 5 other fair value estimates on Revolution Medicines – why the stock might be worth 29% less than the current price!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
Want Some Alternatives?
Markets shift fast. These stocks won’t stay hidden for long. Get the list while it matters:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include RVMD.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com